Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bryan Garnier Lowers AstraZeneca To Buy From Conviction Buy

11/23/2021 | 07:25am EST


© MT Newswires 2021
All news about ASTRAZENECA PLC
04:27aBritain's Oxford Biomedica enters into deal to expand viral vector offerings
RE
03:12aMore Nigerians take up COVID shots after expired doses destroyed
RE
01/27European ADRs Move Higher in Thursday Trading
MT
01/27SAP to buy U.S. fintech Taulia; eyes metaverse opportunities
RE
01/25Valneva Includes Booster Shots in Late-Stage Study of COVID-19 Jab
MT
01/25Valneva Starts Extended Trial to Study Booster Shot of COVID-19 Vaccine; Shares Up 9%
MT
01/25Orange Corners South Africa and AstraZeneca South Africa join forces in a new partnersh..
AQ
01/25Germany to receive 3.8 mln doses of Novavax's new COVID vaccine in Q1
RE
01/25Orange Corners South Africa and AstraZeneca South Africa join forces in a new partnersh..
AQ
01/25Egetis appoints Karl Hård as Head of Investor Relations and Communication
AQ
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 36 228 M - -
Net income 2021 2 276 M - -
Net Debt 2021 24 734 M - -
P/E ratio 2021 59,4x
Yield 2021 2,37%
Capitalization 183 B 184 B -
EV / Sales 2021 5,74x
EV / Sales 2022 4,72x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 118,29 $
Average target price 139,09 $
Spread / Average Target 17,6%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC1.82%183 389
JOHNSON & JOHNSON-0.28%449 095
ROCHE HOLDING AG-6.46%307 637
PFIZER, INC.-9.62%299 559
ABBVIE INC.0.42%240 379
NOVO NORDISK A/S-12.29%219 960